Unassembled CD147 is an endogenous endoplasmic reticulum-associated degradation substrate. by Tyler, Ryan et al.
UC Berkeley
UC Berkeley Previously Published Works
Title
Unassembled CD147 is an endogenous endoplasmic reticulum-associated degradation 
substrate.
Permalink
https://escholarship.org/uc/item/8v60k0dc
Journal
Molecular Biology of the Cell, 23(24)
Authors
Tyler, Ryan
Pearce, Margaret
Shaler, Thomas
et al.
Publication Date
2012-12-01
DOI
10.1091/mbc.E12-06-0428
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
4668 | R. E. Tyler et al. Molecular Biology of the Cell
MBoC | ARTICLE
Unassembled CD147 is an endogenous 
endoplasmic reticulum–associated degradation 
substrate
Ryan E. Tylera, Margaret M. P. Pearcea, Thomas A. Shalerb, James A. Olzmanna, 
Ethan J. Greenblatta, and Ron R. Kopitoa
aDepartment of Biology, Stanford University, Stanford, CA 94305; bSRI International, Menlo Park, CA 94025
ABSTRACT Degradation of folding- or assembly-defective proteins by the endoplasmic retic-
ulum–associated degradation (ERAD) ubiquitin ligase, Hrd1, is facilitated by a process that 
involves recognition of demannosylated N-glycans by the lectin OS-9/XTP3-B via the adaptor 
protein SEL1L. Most of our knowledge of the machinery that commits proteins to this fate in 
metazoans comes from studies of overexpressed mutant proteins in heterologous cells. In 
this study, we used mass spectrometry to identify core-glycoslyated CD147 (CD147(CG)) as 
an endogenous substrate of the ERAD system that accumulates in a complex with OS-9 fol-
lowing SEL1L depletion. CD147 is an obligatory assembly factor for monocarboxylate trans-
porters. The majority of newly synthesized endogenous CD147(CG) was degraded by the 
proteasome in a Hrd1-dependent manner. CD147(CG) turnover was blocked by kifunensine, 
and interaction of OS-9 and XTP3-B with CD147(CG) was inhibited by mutations to conserved 
residues in their lectin domains. These data establish unassembled CD147(CG) as an endog-
enous, constitutive ERAD substrate of the OS-9/SEL1L/Hrd1 pathway.
INTRODUCTION
The endoplasmic reticulum (ER) is the port of entry to the secretory 
pathway and is the site of production of ∼30% of all proteins synthe-
sized in eukaryotic cells (Ghaemmaghami et al., 2003). Accordingly, 
this organelle is enriched in molecular chaperones, isomerases, and 
folding enzymes that are specialized for oxidative protein folding 
and assembly (Hurtley and Helenius, 1989). Because of the harmful 
systemic risks of deploying misfolded or incompletely assembled 
proteins, the ER contains elaborate quality control (QC) machinery 
that monitors the process of protein folding and assembly and en-
sures that only correctly folded proteins are released to distal com-
partments of the secretory pathway (Hammond and Helenius, 1995). 
Ultimately, proteins that fail to meet stringent criteria for deploy-
ment are degraded by cytoplasmic proteasomes in a process known 
as ER-associated protein degradation (ERAD; Smith et al., 2011).
Degradation of proteins by this system is a sequential process 
consisting of 1) recognition/commitment within the ER lumen or 
at the ER membrane, 2) dislocation across the ER membrane, and 
3) degradation by the cytoplasmic ubiquitin–proteasome system 
(UPS). Many of the key components of the mammalian ERAD ma-
chinery have been identified and appear to be organized into a 
modular, distributed network that spans the ER bilayer and is cen-
tered around two membrane-embedded ubiquitin E3 ligases, Hrd1 
and gp78 (Christianson et al., 2012). Tightly coupled reactions en-
sure that dislocated proteins emerging at the cytoplasmic surface of 
the ER are efficiently conjugated with ubiquitin, deglycosylated, and 
degraded by 26S proteasomes. Although considerable progress 
has been made in elucidating the identity and organization of the 
protein components that constitute the core ERAD “machinery,” a 
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copurifying with S-protein affinity-purified (SAP) S peptide–tagged 
OS-9.2 (S-OS-9.2) from digitonin-solubilized HEK293 cells acutely 
infected with a lentivirus expressing shRNA targeting SEL1L or a 
control lentivirus (Table 1 and Supplemental Figure S1B). In lysates 
from control infected cells, S-OS-9.2 interacted robustly (judged 
by total spectral counts [TSC] and number of unique peptides) 
with GRP78/BiP, GRP94, and SEL1L—consistent with our previous 
findings (Christianson et al., 2008)—as well as with known (Mueller 
et al., 2008; Christianson et al., 2012) membrane and cytosolic inter-
actors of the Hrd1 ligase complex, including Hrd1, Ubc6e, Derlin-2, 
and VCP/p97. SEL1L knockdown resulted in a complete loss of 
downstream interactions, confirming the essential role of SEL1L as a 
link between OS-9 and the membrane-embedded Hrd1 ligase and 
its associated membrane and cytoplasmic factors. We also observed 
a concomitant increase in the abundance of Hsp47 and the previ-
ously identified OS-9–interacting luminal chaperones, GRP78/BiP 
and GRP94, after SEL1L knockdown (Christianson et al., 2008).
This analysis also identified a number of proteins that were either 
increased in abundance or detected only in complex with OS-9 
following SEL1L depletion. These proteins could be either SEL1L-
dependent ERAD substrates or ERAD machinery components that 
act upstream of SEL1L. Of those proteins with an increased number 
of unique peptides and/or spectral counts in OS-9.2 complexes that 
were affinity-purified from SEL1L-depleted cells, we identified 
potential ERAD substrates using the following criteria: 1) the pres-
ence of a predicted ER-targeting signal sequence; 2) known or pre-
dicted N-linked glycosylation sites (since we were interested in iden-
tifying potential glycan-dependent ERAD substrates that rely on 
OS-9 for their degradation); and 3) persistent association with S-OS-
9.2 following Triton X-100 solubilization (Table S1), since we have 
previously shown that Triton X-100 disrupts the interaction between 
SEL1L and the Hrd1 ligase complex (and downstream components), 
but not the interaction of S-OS-9.2 with SEL1L or with ectopically 
expressed ERAD substrates (Christianson et al., 2008).
Proteins identified in this analysis that have known associations 
with the protein folding machinery in the ER lumen include Hsp47, 
a collagen-specific chaperone (Ragg, 2007); GRP170/ORP150, an 
atypical chaperone of the Hsp70 family; uridine diphosphate (UDP)-
glucose ceramide glucosyltransferase-like protein 2 (UGGT2); Erdj3, 
a GRP78/BiP cochaperone; and cyclophilin B, an ER peptidyl:prolyl 
isomerase. Several of these proteins—GRP78/BiP, GRP94, GRP170, 
Erdj3, and cyclophilin B—have been previously reported to reside in 
a large, ER-localized multiprotein complex together with another 
UDP-glucose ceramide glycosyltransferase, UGGT1, proposed to 
be involved in the folding and maturation of immunoglobulin (Ig) 
light chains (Meunier et al., 2002). Based on the above criteria, the 
group of potential ERAD substrates included procollagen-lysine, 
2-oxoglutarate 5-dioxygenase (PLOD2), the nuclear pore protein 
NUP210, and the Ig superfamily member CD147, which is also 
known as basigin or EMMPRIN. We also detected two additional 
proteins, the glycosyltransferase 25 family members 1 (GLT25D1) 
and 3 (CERCAM). However, because of the low apparent abundance 
of the latter in the SAPs (estimated from TSC), and because the 
abundance of PLOD2 or NUP210 did not increase following treat-
ment of cells with the proteasome inhibitor MG132 (unpublished 
data), we chose to focus our attention on CD147.
Inefficient biosynthetic processing and proteasome-
mediated degradation of CD147
CD147 (Figure 1A) is a 269–amino acid, type I transmembrane (TM) 
glycoprotein, ubiquitously expressed in chordates, with reported 
roles in a multitude of cellular processes, including spermatogenesis, 
critical unanswered question is how proteins are recognized as sub-
strates of this process and how they are delivered to the membrane-
embedded complex for dislocation to the cytoplasm, and subse-
quent processing by the downstream UPS.
One prominent hypothesis posits that recognition of specific 
trimmed mannose structures on core N-glycans serves as a critical 
signal committing proteins bearing these marks to the degradative 
fate (Helenius and Aebi, 2004). The vast majority of proteins enter-
ing the secretory pathway are modified by a canonical triantennary 
N-linked glycan, and progressive removal of terminal mannose resi-
dues from this glycan by luminal mannosidases serves as a “timer” 
to monitor the processes of polypeptide folding and assembly. OS-9 
and XTP3-B are ER luminal-resident lectins that bind selectively to 
N-glycans bearing a terminal C-branch α-1,6-linked mannose (Satoh 
et al., 2010; Yamaguchi et al., 2010) and to SEL1L, a subunit of the 
membrane-embedded Hrd1 E3 ubiquitin ligase complex (Christian-
son et al., 2008; Mueller et al., 2008). Accordingly, proteins that are 
slow to fold or fail to fold within the ER lumen become enzymatically 
demannosylated, causing them to be bound by OS-9/XTP3-B and 
subsequently delivered to the Hrd1 ligase complex via SEL1L. How-
ever, the functional relationship between these two lectins and their 
precise roles in the commitment of proteins to ERAD is unclear, in 
part because of the lack of an absolute requirement for N-glycans in 
ERAD (proteins lacking N-glycans are still degraded in a manner 
dependent on OS-9 or its yeast orthologue Yos9p [Denic et al., 
2006; Christianson et al., 2008]) and because the association of 
SEL1L with OS-9 and XTP3-B is blocked by mutations in their lectin 
domains that disrupt conserved contacts with the glycan (Christian-
son et al., 2008). Although there is compelling evidence to support 
a role for demannosylation in the commitment of proteins to ERAD, 
the relationship between OS-9 and XTP3-B and the role of N-glycans 
in the interaction of these two lectins with substrates and down-
stream machinery remains unclear.
Did ERAD evolve simply to eliminate proteins that, because of 
mutation or amino acid misincorporation, are unable to acquire 
native secondary or tertiary structures? Because most ERAD stud-
ies to date have focused on the degradation of mutant, folding- or 
assembly-defective proteins or orphan subunits of oligomeric 
complexes that are typically overexpressed in heterologous sys-
tems, little is known of “natural” or endogenous substrates of this 
QC system. In a previous study, we reported that the amount of an 
exogenous ERAD substrate, the folding-defective null Hong Kong 
(NHK) variant α-1 antitrypsin, copurifying with S peptide-tagged 
OS-9 was dramatically increased following short hairpin RNA 
(shRNA)-mediated depletion of SEL1L (Christianson et al., 2008). 
This finding, in addition to confirming a requirement for SEL1L in 
promoting the release of substrates from OS-9 to downstream 
ERAD components, such as Hrd1, provided an approach with 
which to identify endogenous substrates of the OS-9/SEL1L/Hrd1 
ligase ERAD system. In the present study, we have exploited those 
observations and used affinity-capture liquid chromatography–
tandem mass spectrometry (LC-MS/MS) to identify endogenous 
proteins that copurify with affinity-tagged OS-9.2 in the absence of 
SEL1L. Using this approach, we have identified and confirmed 
core-glycosylated CD147 to be a glycan-dependent substrate of 
the OS-9/SEL1L/Hrd1 ligase pathway.
RESULTS
Identification of endogenous glycan-dependent ERAD 
substrates
To identify endogenous substrates of the OS-9/SEL1L/Hrd1ligase 
ERAD pathway, we used LC-MS/MS analysis to identify proteins 
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cells treated with cycloheximide (Figure 1D) indicated that while 
CD147(Mat.) was stable, CD147(CG) immunoreactivity disappeared 
over the 6-h treatment period. Metabolic pulse–chase analysis 
(Figure 1E) confirmed that CD147(CG) is unstable, with a half-life of 
∼90 min (Figure 1F), while the mature glycoform remained stable 
over the 10-h chase period (Figure 1G). The proteasome inhibitor 
MG132 increased the stability of CD147(CG), leading to the accu-
mulation of a slightly faster-migrating CD147 species, reflecting 
continued enzymatic demannosylation of this glycoform (see The 
role of ER lectins in CD147(CG) degradation.). MG132 treatment 
did not increase steady-state levels of CD147(CG) but did lead to 
the appearance of a deglycosylated (DeG) form of CD147 (Figure 
S2A), presumably representing a dislocated degradation intermedi-
ate. The incomplete stabilization of CD147(CG) by MG132 in the 
pulse–chase analysis could reflect a contribution of nonproteasomal 
degradation pathways; however, treatment of cells with inhibitors of 
lysosomal hydrolases failed to increase the stability of CD147(CG) or 
to lead to the appearance of CD147(DeG) (Figure S2, A and B). It is 
also possible that MG132 treatment leads to conversion of a frac-
tion of stabilized CD147(CG) into high-molecular-weight, heteroge-
neous polyubiquitin conjugates that may not be well-resolved by 
SDS–PAGE, as has been observed for other integral membrane 
T-cell activation, cell adherence, metastasis, and neuronal develop-
ment (reviewed in Iacono et al., 2007). Structurally, CD147 is com-
posed of an ectodomain containing three confirmed N-glycans (Tang 
et al., 2004), an amino-terminal Ig C2–type domain, a membrane-
proximal Ig V–type domain, a TM domain, and a short cytoplasmic 
tail of ∼60 residues. Immunoblot analysis (Figure 1B) revealed that 
endogenous CD147 is expressed at steady state in HEK293 cells, as 
in other cell types (Figure S2B; Tang et al., 2004; Yu et al., 2006), as 
a mixture of ∼35 kDa endoglycosidase H (Endo H)–sensitive and 
∼45–60 kDa Endo H–insensitive glycoforms that correspond to core-
glycosylated (CG) ER-localized and mature (Mat.) polylactosamine-
modified (Tang et al., 2004), plasma membrane–localized (Gallagher 
et al., 2007) species, respectively. Only the CG glycoform was cap-
tured with S-OS-9.2; its abundance increased sharply after SEL1L 
depletion (Figure 1C), confirming our MS analysis and the localiza-
tion of the CG form to the ER. The S-OS-9.1 splice variant also inter-
acted with CD147(CG) upon SEL1L depletion (unpublished data), 
consistent with previous studies showing that both OS-9 splice 
variants interacted with the ERAD substrate NHK α-1 antitrypsin 
(Christianson et al., 2008).
We used translational shut-off assays to initially assess the stabili-
ties of CD147 glycoforms. Immunoblot analysis of CD147 in HEK293 
Controlc SEL1L shRNAd
Symbola Uniprot ID Protein name Topologyb TSCe Peptides TSCe Peptides
OS9 Q13438 OS-9 L 165 58 455 108
HSPA5 P11021 GRP78 / BiP L 179 50 297 63
HSP90B1 P14625 GRP94 L 149 54 200 62
SEL1L Q9UBV2 SEL1L TM 21 10
VCP P55072 p97/VCP TMf 16 10
SYVN1 Q86TM6 Hrd1 TM 3 1
DERL2 Q9GZP9 Derlin-2 TM 1 1
UBE2J1 Q9Y385 UBC6e TM 1 1
SERPINH1 P50454 Hsp47 L 7 4 33 14
HYOU1 Q9Y4L1 GRP170 L 13 8
UGCGL2 Q9NYU1 UGGT2 L 10 6
FOXRED2 Q8IWF2 ERFAD L 3 2
DNAJB11 Q9UBS4 Erdj3 L 2 1
PPIB P23284 Cyclophilin B L 2 1
PLOD2 O00469 Procollagen-lysine, 2-oxoglutarate 
5-dioxygenase 2
L 5 3 24 15
NUP210 Q8TEM1 POM210 TM 12 8
EMMPRIN P35613 CD147 TM 7 3
GLT25D1 Q8NBJ5 Glycosyltransferase 25 family 
member 1
L 2 2
CERCAM Q5T4B2 Glycosyltransferase 25 family 
member 3
L 2 1
aGene name.
bL, lumenal protein; TM, transmembrane domain–containing protein.
cHEK293 cells infected with an empty lentivirus, not expressing an shRNA.
dHEK293 cells infected with a lentivirus targeting SEL1L.
eTSC, total spectral counts.
fp97/VCP is a cytoplasmic protein that is localized to the ER membrane.
TABLE 1: LC-MS/MS analysis of S-OS-9.2 affinity-purified complexes from digitonin-solubilized cell lysates.
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does not accumulate as high-molecular-weight polyubiquitinated 
species following exposure to proteasome inhibitor. Proteasome in-
hibition can also cause some dislocated ERAD substrates to become 
insoluble in nonionic detergents (Yu et al., 1997), which would lead 
ERAD substrates (Gelman et al., 2002). However, enzymatic deubiq-
uitination of lysates from MG132-treated cells (Figure S2C) did not 
result in increased abundance of either core-glycosylated or degly-
cosylated CD147, suggesting that a significant fraction of CD147 
FIGURE 1: Identification of CD147 as a putative ERAD substrate. (A) Diagram depicting the human CD147 protein and 
important features (SS, signal peptide; Ig, immunoglobulin domain; TM, transmembrane domain). Peptides identified in 
LC-MS/MS analysis of S-OS-9.2 affinity purifications are shown. (B) Profile of CD147 expression in Triton X-100–
solubilized whole-cell HEK293 lysates treated with or without Endo H (Mat., mature; CG, core-glycosylated; DeG, 
deglycosylated). (C) HEK293 cells expressing S-OS-9.2 and infected with lentivirus expressing an shRNA targeting SEL1L 
(+) or an empty virus as a control (−) were solubilized in 1% digitonin, and S-OS-9.2 complexes were affinity-purified 
from cell lysates and probed for the indicated proteins. (D) CD147 turnover was assessed by immunoblotting Triton 
X-100 cell extracts for CD147 after treating cells with cycloheximide for the indicated times. (E) Autoradiogram of a 
CD147 pulse–chase analysis in HEK293 cells treated with either dimethyl sulfoxide (DMSO; control) or 10 μM MG132 
during the chase period. CD147 was isolated from cell lysates with anti-human CD147 8G6, and immunoprecipitates 
were separated by SDS–PAGE and analyzed with a phosphorimager. (F and G) Quantification of the pulse–chase data 
experiment from (E), in which degradation of CG and formation of Mat. glycoforms of CD147 are calculated as a percent 
of starting CG material. CTL, control; IB, immunoblot; SAP, S-peptide affinity purification; S-protein, S-protein-HRP.
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Knockdown of endogenous Hrd1, but not gp78, strongly stabi-
lized CD147(CG), but had no measurable effect on the stability of 
the mature glycoform or the efficiency of CD147(CG) maturation, as 
assessed by pulse–chase analysis (Figure 2, C–E). In the absence of 
Hrd1, CD147(CG) gradually became converted to a faster-migrating 
species, most likely reflecting a prolonged exposure to ER mannosi-
dases (see The role of ER lectins in CD147(CG) degradation) and 
suggesting Hrd1 is essential for CD147(CG) dislocation to the cyto-
plasm. Knockdown of SEL1L also stabilized CD147(CG) and led 
to the accumulation of demannosylated glycoforms (Figure 2C), 
although the extent of CD147(CG) stabilization was less than that 
observed after Hrd1 knockdown.
The role of ER lectins in CD147(CG) degradation
CD147(CG) was strongly stabilized by kifunensine, a selective inhibi-
tor of type I α-mannosidases (Elbein et al., 1990), demonstrating 
that enzymatic demannosylation is essential for degradation of un-
assembled CD147(CG) subunits (Figure 3, A and B). The small in-
crease in mobility of CD147(CG) observed during the pulse–chase 
analyses (Figures 2C and 3A) confirms that CD147 is itself a sub-
strate of this mannosidase activity. We observed partial stabilization 
of CD147(CG) by depletion of the ER lectins OS-9 and XTP3-B 
(Figure 3, C and D), suggesting that these lectins may facilitate the 
delivery of immature CD147(CG) to the Hrd1 ligase complex. 
Although both lectins have mannose-6-phosphate receptor homol-
ogy (MRH) domains that bind selectively to the same terminal α-
1,6–linked mannose glycans (Satoh et al., 2010), SEL1L depletion 
had opposite effects on their association with CD147(CG), causing 
increased association with S-OS-9.2 (Figure 3E) but decreased inter-
action with XTP3-B-S (Figure 3F). In addition, the interaction of these 
lectins with CD147(CG) was differentially sensitive to detergents, 
with the S-OS-9.2–CD147(CG) interaction remaining stable in Triton 
X-100, and the XTP3-B-S–CD147(CG) interaction being Triton X-100 
labile (Figure 3G). These data suggest that these two lectins interact 
with CD147(CG) in fundamentally different ways. Mutation of con-
served residues identified in the crystal structure of the OS-9 MRH 
domain to make critical contacts with trimmed core glycans (Satoh 
et al., 2010) largely abolished the ability of both S-OS-9.2 (after 
SEL1L knockdown; Figure 4A) and XTP3-B-S (Figure 4B) to capture 
CD147(CG), confirming that the interaction between these ER lec-
tins and CD147(CG) occurs between the lectin domain and a spe-
cific glycan structure containing a terminal C-branch α-1,6–linked 
mannose. This requirement for a mannosidase-trimmed glycan 
structure in the interaction of OS-9 with CD147(CG) was assessed by 
affinity purification of S-OS-9.2 from kifunensine-treated, SEL1L-
depleted cells. As was seen in the pulse–chase analyses, the steady-
state population of CD147(CG) from kifunensine-treated cells exhib-
ited a slower mobility than control-treated cells, indicating an 
inhibition of mannosidase-mediated trimming (Figure 4C). The man-
nosidase inhibition resulted in a significant decrease in the amount 
of CD147(CG) copurifying with S-OS-9.2, demonstrating that OS-9’s 
interaction with CD147(CG) not only requires its MRH domain but 
also a mannosidase-trimmed glycan on CD147(CG).
DISCUSSION
While the use of exogenous model ERAD substrates has led to im-
portant mechanistic insights into how misfolded and unassembled 
secretory proteins are degraded, our understanding of this pathway 
is substantially limited by the paucity of known bona fide endoge-
nous substrates. In this study, we sought to identify novel endoge-
nous ERAD substrates by using a proteomic strategy to identify 
proteins that accumulate in complex with the substrate recognition 
to an underestimation of total CD147(CG) recovery. However, we 
observed no difference in the amount of either CD147 glycoform 
from MG132-treated cells solubilized with Triton X-100 or SDS (un-
published data). Interestingly, we did observe the appearance of an 
CD147 immunoreactive species that migrates on SDS–PAGE with 
faster mobility than the deglycosylated form (Figure S2C), raising 
the possibility that, in the presence of MG132, CD147 may be still 
be subject to limited proteolysis. We cannot rule out the possibility 
that the trypsin-like or postacidic activities of the 20S proteasome, 
which are not effectively inhibited by MG132 (or indeed by other 
proteasome inhibitors; Kisselev et al., 2012), could also contribute 
to the generation of these fragments in the presence of MG132. It is 
also possible that CD147 could be proteolytically processed by an 
intramembrane protease like the rhomboid protease RHBDL4, 
which has recently been described to be present in the ER, where it 
contributes to the degradation of ERAD substrates that, like CD147, 
contain a charged residue within the membrane-spanning segment 
(Fleig et al., 2012).
The gradual appearance of CD147(Mat.) coincident with 
CD147(CG) disappearance (Figure 1E) suggests a precursor–prod-
uct relationship between the two major CD147 glycoforms typical of 
protein maturation into post-ER compartments. Quantification of 
the pulse–chase data revealed that endogenous CD147 (CG) is 
converted to the mature glycoform with only 25–30% efficiency 
(Figure 1G). Stabilization of immature CD147 by MG132 did not in-
crease the fraction converted to the mature form, suggesting, per-
haps, that CD147 maturation in the ER depends on the presence 
of one or more limiting factors. These data suggest that CD147(CG) 
is inefficiently processed in the ER and that the majority of newly 
synthesized CD147(CG) is degraded by the proteasome.
Degradation of CD147(CG) requires the Hrd1 ubiquitin 
ligase complex
The mammalian ERAD network is organized around two key ubiq-
uitin ligases, Hrd1 and gp78 (Ye et al., 2005; Chen et al., 2006; 
Christianson et al., 2012). These two ligases share a similar topologi-
cal organization within the ER membrane, interact with an overlap-
ping set of proteins, and exhibit distinct specificities for different 
ERAD substrates. Hrd1, but not gp78, forms a complex with SEL1L 
and OS-9 that facilitates the degradation of substrate proteins by 
the UPS (Mueller et al., 2008; Christianson et al., 2012). A role for 
Hrd1 in CD147 degradation was suggested by the detection of 
CD147 in LC-MS/MS analysis of Hrd1-S SAPs from digitonin-solubi-
lized cell lysates (unpublished data; Christianson et al., 2012). Im-
munoblot analysis confirmed the presence of CD147(CG) in pro-
teins captured with Hrd1-S, but not with gp78-S (Figure 2A), and 
endogenous Hrd1, but not gp78, was readily detected in CD147 
immunoprecipitates from control HEK293 cells but not from those 
lacking SEL1L (Figure 2B). Thus endogenous CD147(CG) interacts 
specifically with endogenous Hrd1 in a SEL1L-dependent manner in 
HEK293 cells.
Mature CD147 forms a stoichiometric complex with the mono-
carboxylic acid transporters MCT1, MCT3, and MCT4 (Kirk et al., 
2000; Wilson et al., 2002; Fanelli et al., 2003), and previous studies 
have demonstrated that association of MCT1 and CD147(CG) in 
the ER is essential for the maturation of both proteins to post-ER 
compartments (Kirk et al., 2000; Gallagher et al., 2007). MCT1 
was readily detected in immunoprecipitates with CD147 antibody 
(Figure 2B), but was undetectable following affinity capture with 
Hrd1-S (Figure 2A) or S-OS-9.2 (Figure S3). Thus the pool of 
CD147(CG) in cells partitions between degradation via OS-9/SEL1L/
Hrd1 and maturation via association with MCT1.
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substrate. CD147 is not the first described constitutive substrate of 
the OS-9/SEL1L/Hrd1 E3 ligase pathway. A carboxy-terminal frag-
ment of the hedgehog ligand generated by an intein-like self-cleav-
age of the hedgehog ligand precursor (Chen et al., 2011) was re-
cently shown to be a substrate of Hrd1-dependent ERAD and major 
histocompatibility complex (MHC) class I heavy chains synthesized 
in the absence of their oligomeric partner; β2 microglobulins are 
factor OS-9 following depletion of the downstream ERAD adaptor 
SEL1L. Among the proteins that increased in abundance in the ab-
sence of SEL1L were luminal chaperones, cochaperones, and pro-
teins with known or inferred roles in protein folding, as well as po-
tential substrates of OS-9– and SEL1L-dependent ERAD. This study 
identified CD147, a ubiquitously expressed TM protein that is a 
member of the Ig superfamily, as a constitutive endogenous ERAD 
FIGURE 2: Degradation of CD147(CG) is mediated by the Hrd1-SEL1L E3 ligase complex. (A) HEK293 cells expressing 
either gp78-S or Hrd1-S were lysed in 1% digitonin, and S-protein affinity-purified complexes were immunoblotted for 
the indicated proteins. (B) Cells infected with either control (−) or SEL1L (+) shRNA-expressing retrovirus were lysed in 
1% digitonin, and anti-CD147 immunoprecipitates were probed for the indicated proteins. IB, immunoblot; SAP, 
S-peptide affinity purification; IP, immunoprecipitation. (C) Pulse–chase analysis of CD147 in HEK293 cells infected with 
retroviruses harboring shRNAs that target firefly luciferase (FF, control), Hrd1, SEL1L, or gp78. Anti-CD147 
immunoprecipitates were separated by SDS–PAGE and analyzed on a phosphorimager. KD, knockdown. (D and E) 
Quantification of the data in (C) for CD147(CG) degradation (D) or formation of CD147 (Mat.). (E) Each time point 
represents the average of three independent experiments. The error bars represent the SEM. 
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FIGURE 3: The role of N-glycans and the ER lectins OS-9 and XTP3-B in the degradation of CD147(CG). (A) Pulse–chase 
analysis of CD147 in cells stably transduced with retroviruses expressing shRNAs targeting firefly luciferase (FF, control), 
in the presence of vehicle control (DMSO) or 5 μg/ml kifunensine during the chase. Cells stably expressing shRNAs 
targeting Hrd1 were also analyzed as a positive control. Anti-CD147 immunoprecipitates were separated by SDS–PAGE 
and analyzed on a phosphorimager. (B) Quantification of the data in (A) for CD147(CG) turnover. (C) Pulse–chase analysis 
of CD147 in HEK293 cells infected with retroviruses expressing shRNAs that target firefly luciferase (FF, control) XTP3-B 
or OS-9. Anti-human CD147 immunoprecipitates were separated by SDS–PAGE and analyzed on a phosphorimager. 
(D) Quantification of the data in (C) for CD147(CG) turnover, with each time point representing the average of at least 
three independent experiments. Error bars represent SEM. (E) HEK293 cells were cotransfected with vectors expressing 
S-OS-9.2 and shRNAs targeting SEL1L (+) or firefly luciferase (−). S-OS-9.2 complexes were affinity-purified from 1% 
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to the regulation of intracellular pH in cells 
with high glycolytic activity (Kirk et al., 2000; 
Wilson et al., 2002; Gallagher et al., 2007). 
Previous studies have indicated that the 
mechanisms regulating the cellular levels of 
each of these proteins are quite distinct. 
MCT1 and MCT4 are transcriptionally up-
regulated during cellular adaptation to in-
creases in glycolytic flux and anaerobic con-
ditions (Fanelli et al., 2003; Ullah et al., 2006; 
Le Floch et al., 2011), while CD147 transcrip-
tion is relatively constitutive (Fanelli et al., 
2003). This apparent “overcapacity” of con-
stitutively expressed CD147 ensures a dy-
namic supply of CD147(CG) to drive the as-
sembly of mature MCT complexes in 
response to changing metabolic demand, 
and is reminiscent of the proposed mecha-
nism of assembly of the T-cell receptor, in 
which α-subunits that are synthesized in ex-
cess of their heterooligomeric partners are 
constitutively degraded (Chen et al., 1988).
Although the details of how MCT1/4 
and CD147 coassemble in the ER mem-
brane are not well understood, it has been 
suggested that a highly conserved gluta-
mate residue in the middle of CD147’s sin-
gle TM helix contributes to its assembly 
with MCT1 and MCT4, possibly via an in-
tramembrane charge-pair interaction with 
a highly conserved arginine residue in the 
eighth TM domain in MCTs (Kirk et al., 
2000; Manoharan et al., 2006). This para-
digm is also reminiscent of the assembly of 
the T-cell receptor, in which intramembrane 
charge-pair interactions promote assembly 
of the heterooligomeric complex (Cosson 
et al., 1991). It has also been proposed 
that unpaired charges in TM domains 
serve as degrons to promote the ERAD of 
unassembled TCRα and CD3δ subunits 
(Bonifacino et al., 1990, 1991), but addi-
tional factors appear to influence the ability of such unpaired TM-
charged residues to serve as degrons (Lankford et al., 1993; Shin 
et al., 1993). It is tempting to speculate that the putative dual func-
tions in protein complex assembly and degradation attributed to 
intramembrane paired and unpaired charge interactions could 
contribute to both assembly of MCT1/4-CD147 complexes and 
direct excess unassembled CD147(CG) molecules to ERAD. How-
ever, this hypothesis has proven difficult to test because exoge-
nously expressed, epitope-tagged versions of CD147 do not par-
tition between assembly and ERAD in a manner reflecting the 
behavior of the endogenous protein (unpublished data).
Our data reveal that CD147(CG) is strongly stabilized by Hrd1 
silencing and kifunensine treatment, indicating an essential role for 
also degraded in a Hrd1-dependent manner (Burr et al., 2011). 
Chordates express two other closely related proteins, neuroplastin/
SDR1 (Fossum et al., 1991) and the teratocarcinoma antigen GP70/
embigin (Iacono et al., 2007), in addition to CD147, with a common 
domain organization and nearly identical TM domain sequences. 
The close similarity of these analogues to CD147 suggest they may 
also be degraded via ERAD and, along with CD147, may make up a 
new class of glycan-dependent endogenous substrates of the OS-9/
SEL1L/Hrd1 E3 ligase degradation pathway.
CD147 is an obligatory assembly factor for several membrane 
transporters, of which the best characterized are the monocarboxy-
late cotransporters MCT1 and MCT4, which mediate proton-depen-
dent efflux of lactate and pyruvate from cells and hence contribute 
digitonin-solubilized cell lysates and analyzed by immunoblotting for the indicated proteins. (F) HEK293 cells stably 
expressing XTP3-B-S were transduced with lentiviruses harboring shRNAs targeting SEL1L (+) or firefly luciferase (−). 
S-protein-affinity purifications from 1% digitonin-solubilized lysates were processed as in (E). (G) S-OS-9.2 or XTP3-B-S 
affinity-purified complexes were isolated from cells expressing firefly luciferase (−) or SEL1L (+) shRNAs and lysed in 1% 
Triton X-100. * indicates nonspecific immunoreactive bands in (E) and (G). IB, immunoblot. SAP, S-peptide affinity 
purification; KD, knockdown.
FIGURE 4: Glycan dependence of the interaction of OS-9 and XTP3-B with CD147(CG). 
(A) HEK293 cells were cotransfected with wild-type S-OS-9.2 or the indicated S-OS-9.2 MRH 
domain mutant together with shRNAs targeting firefly luciferase (−) or SEL1L (+). S-OS-9.2 
complexes were affinity-purified from 1% digitonin-solubilized cell lysates and analyzed by 
immunoblotting for the indicated proteins. (B) HEK293 cells were transfected with wild-type 
XTP3-B-S or the indicated XTP3-B-S MRH domain mutants, and affinity-purified complexes from 
1% digitonin-solubilized cell lysates were analyzed by immunoblotting for the indicated proteins. 
(C) S-OS-9.2 affinity-purified complexes from 1% Triton X-100–solubilized cell lysates were 
isolated from cells expressing shRNAs targeting SEL1L and treated with either DMSO (−) or 
5 μg/ml kifunensine (+), and probed for the indicated proteins. IB, immunoblot. SAP, S-peptide 
affinity purification. S-protein, S-protein-HRP.
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itself be degraded in a SEL1L/Hrd1-dependent manner, perhaps re-
flecting codegradation of OS-9, along with its bound substrates. 
Further study will be needed to elucidate the different roles that 
OS-9 and XTP3-B contribute to the recognition and commitment of 
unassembled or misfolded proteins in the early secretory pathway.
MATERIALS AND METHODS
Cell culture and transfection
HEK293 and 293T cells were cultured in DMEM containing 4.5 g/l 
glucose and l-glutamine (Mediatech, Manassas, VA), and supple-
mented with 10% FetalPlex animal serum complex (ASC; Gemini 
Bio-Products, West Sacramento, CA) at 37°C and 5% CO2. Transfec-
tion was carried out using a standard calcium-phosphate coprecipi-
tation technique (Kingston et al., 2001). Stable cell lines were se-
lected in 1 mg/ml G418 (Invitrogen, Carlsbad, CA), cloned by 
limiting dilution, and thereafter maintained in 500 ng/ml G418. 
Where indicated, cells were treated with MG132 (Enzo Life Sciences, 
Farmingdale, NY), cycloheximide (Sigma-Aldrich, St. Louis, MO), or 
kifunensine (Cayman Chemicals, Ann Arbor, MI). Endo H was from 
NEB (Ipswich, MA).
Plasmids and antibodies
Plasmids for expression of S-peptide epitope-tagged OS-9.1, OS-
9.2, OS-9.2(R188A), Hrd1, XTP3-B, SEL1L, and gp78 have been 
described previously (Christianson et al., 2008, 2012). The W117A/
W118A double point mutation was introduced into S-OS-9.2 
cDNA by site-directed mutagenesis using the primers 5′-CTGCT-
TGCTGAAGACAAAGGACGCGGCGACATATGAATTCTGT-
TATG-3′ and 5′-CATAACAGAATTCATATGTCCACCAGTCCTTT-
GTCTTCAGCAAGCAG-3′, using the QuikChange Site-Directed 
Mutagenesis Kit (Agilent, Santa Clara, CA). pSUPERSTAR shRNA 
expression constructs targeting SEL1L have been described previ-
ously (Christianson et al., 2008, 2012).
Rabbit polyclonal antibodies used include: anti–CD147 “B10” 
(Sun and Hemler, 2001; a gift from Martin Hemler, Harvard Univer-
sity), anti–OS-9 and anti–XTP3-B (Christianson et al., 2008), anti-
SEL1L (a gift from H. Ploegh, Whitehead Institute for Biomedical 
Research), anti-Hrd1 and anti-gp78 (gifts from R. Wojcikiewicz, 
SUNY Upstate Medical University), and anti-MCT1 (a gift from 
Nancy Philp, Thomas Jefferson University). Mouse monoclonal an-
tibodies used included anti-CD147 hybridoma clone 8G6 
(Berditchevski et al., 1997; a gift from Martin Hemler, Harvard Uni-
versity), anti-CD147 clone A-12 (Santa Cruz Biotech nology, Santa 
Cruz, CA), anti–S-peptide (EMD Millipore, Billerica, MA), anti-ubiq-
uitin clone P4G7 (Covance, Princeton, NJ), and anti-GAPDH 
(EMD Millipore). Rabbit polyclonal anti–S-peptide was generated 
by immuni zing rabbits with KLH-conjugated S-peptide, after which 
the sera were affinity-purified (Covance).
The S-protein-horseradish peroxidase (HRP) conjugate was 
purchased from Novagen. Anti-rabbit and anti-mouse secondary 
antibody-HRP conjugates were from GE Healthcare Life Sciences, 
Pittsburgh, PA.
Viral vectors and virus production
A list of the viruses and shRNA sequences used in these studies can 
be found in the table in Figure S1F. The lentivirus vector containing 
an shRNA targeting SEL1L was created by subcloning the ClaI/EcoRI 
fragment from the pSUPERSTAR-SEL1L construct into pLVTHM ac-
cording to the Trono Lab (University of Geneva) protocol found at 
www.addgene.org (Wiznerowicz and Trono, 2003). Empty pLVTHM 
not containing an shRNA sequence was used as a negative control. 
The pRetroQ retrovirus vector targeting OS-9 and the control 
this ubiquitin ligase and for enzymatic demannosylation in its degra-
dation. It is therefore somewhat curious that knockdown of SEL1L 
and OS-9 did not stabilize CD147(CG) to a similar extent. This dis-
crepancy could be due to incomplete knockdown or could indicate 
that some CD147(CG) can be delivered to Hrd1 independently of 
SEL1L and OS-9, as is the case for NHK α-1 antitrypsin (Christianson 
et al., 2008) and the integral membrane substrate GluR1 (Christianson 
et al., 2012) in HEK293 cells, and some ERAD substrates in yeast 
(Denic et al., 2006; Sato et al., 2009). It is also possible that XTP3-B 
and OS-9 have partially redundant functions in CD147(CG) degra-
dation, as has been reported for the degradation of a truncated 
fragment of β-secretase (BACE476Δ; Bernasconi et al., 2010), but 
we did not observe enhanced stabilization of CD147(CG) in cells 
expressing a stable XTP3-B knockdown that were also transiently 
transfected with OS-9 shRNA or in cells transiently cotransfected 
with both OS-9 and XTP3-B shRNAs (unpublished data), suggesting 
that, in the case of CD147(CG), these two lectins do not operate in 
a redundant manner. This result is not altogether surprising in light 
of a previous study reporting that these two lectins act as inter-
changeable ERAD shuttles only for proteins such as BACE476Δ that 
lack TM domains, and not for proteins such as CD3δ that, similar to 
CD147(CG), contain destabilizing TM degrons (Bernasconi et al., 
2010). Indeed, our observation that SEL1L depletion has opposing 
effects on the interaction between CD147(CG) and these two lec-
tins, together with the observation that the XTP3-B–CD147(CG) 
complex is disrupted by Triton X-100, while the OS-9–CD147(CG) 
complex is not, argues against simple redundancy and suggests that 
the lectins interact with CD147(CG) in different ways. Although our 
data clearly demonstrate CD147(CG) to be a substrate for mannosi-
dase trimming, to interact with OS-9 and XTP3-B, and to be stabi-
lized by kifunensine, they do not provide evidence for (or against) a 
causal relationship between trimming of terminal mannose residues 
on CD147(CG) and its degradation. Many components of the ERAD 
machinery, including SEL1L, OS-9, and XTP3-B are themselves 
N-glycosylated, and recent data suggest that their glycans are also 
substrates for kifunensine-sensitive demannosylation (M.M.P.P. and 
R.R.K., unpublished data). Our observation that the amount of 
CD147(CG) copurifying with XTP3-B decreased following SEL1L 
depletion suggests that the interaction between CD147(CG) and 
XTP3-B may be mediated by a third protein, perhaps SEL1L, while 
the interaction between CD147(CG) and OS-9 is likely to occur 
through direct binding of OS-9’s MRH domain to a trimmed glycan 
on CD147(CG). Clearly, further study will be needed to fully under-
stand how glycan trimming and luminal lectins collaborate with the 
SEL1L and Hrd1 complex for different ERAD substrates.
In SEL1L-depleted cells, OS-9 was found to be associated with a 
set of chaperones and folding enzymes, including GRP170/ORP150, 
UGGT2, ERFAD, Erdj3, and cyclophilin B that have previously been 
reported to form a protein complex associated with unassembled, 
incompletely folded Ig heavy chains (Meunier et al., 2002). We pro-
pose that SEL1L depletion creates a “logjam” of malfolded proteins 
in the ER lumen akin to the situation in cells expressing unassembled 
Ig heavy chains, leading to the recruitment of a complex rich in mo-
lecular chaperones and folding enzymes. Why this protein complex 
is associated with OS-9 under conditions of SEL1L depletion is less 
clear. In the absence of SEL1L, it is probable that the malfolded pro-
teins associated with this complex are enriched in demannosylated 
glycans and hence bind OS-9. Furthermore, all of the members of 
this complex are glycoproteins and might themselves therefore be 
susceptible to demannosylation, enabling them to be bound by the 
OS-9 MRH domain. Finally the observed increase in total S-OS-9.2 
abundance following SEL1L knockdown suggests that OS-9 may 
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blottings were stripped off by Pierce Restore Western Blot Strip-
ping Buffer prior to subsequent immunoblot analysis.
Radiolabeling and pulse–chase analysis
Prior to radiolabeling, 1.8 × 106 HEK293 cells were plated on poly-l-
lysine–coated plates in complete media. The next day, the cell 
monolayers were washed twice with “cold” labeling media contain-
ing DMEM, 4.5 g/l glucose and sodium pyruvate, l-methionine, l-
cysteine, penicillin–streptomycin, and 10% dialyzed ASC. The cells 
were then starved in cold media lacking l-methionine and l-cysteine 
for 15 min; this was followed by radiolabeling in media containing 
125 μCi/ml 35S-labeled cysteine/methionine (Easytag Express Pro-
tein Labeling Mix 35S; Perkin Elmer-Cetus, Waltham, MA) for 30 min. 
The cell monolayers were then quickly washed twice with 3 ml of 1X 
Hanks Buffered Saline Solution (Invitrogen) and chased in complete 
media supplemented with cold cysteine and methionine added to a 
final concentration of 2.5 mM each. At specified time points follow-
ing this, the cells were harvested in ice-cold 1X PBS and collected by 
centrifugation, and the pellets were frozen and stored at −80°C. Cell 
pellets were lysed in buffer containing 50 mM Tris (pH 7.4), 150 mM 
NaCl, 5 mM EDTA, 0.5% (wt/vol) sodium deoxycholate, 1% (vol/vol) 
Triton X-100, and protease inhibitors (Roche) at 4°C for 1 h while 
mixing. The lysates were cleared by centrifugation at 20,000 × g for 
15 min at 4°C, and normalized according to labeling specificity us-
ing trichloroacetic acid (TCA) precipitation of proteins, as previously 
described (Ward and Kopito, 1994). Lysates were precleared with 
protein G beads (GenScript, Piscataway, NJ) for 2 h at 4°C with mix-
ing. CD147 was then immunoprecipitated by incubation with 5 μg 
of mouse 8G6 antibody and protein G beads overnight at 4°C with 
mixing. Immunoprecipitated proteins were washed three times in 
lysis buffer, eluted by boiling in Laemmli buffer, and separated by 
SDS–PAGE, and the gels were dried. The radioactive bands were 
detected and quantified on a phosphorimager (Molecular Dynam-
ics, Sunnyvale, CA). The percent CG (%CG) for CD147(CG) and 
CD147(Mat.) was calculated by dividing the phophorimager CG or 
Mat. band intensity at a specific time by that of the CG at the t = 0 
time point and then multiplying by 100%.
Deubiquitination of cellular extracts
HEK293 cells incubated in the presence or absence of MG132 
for 12 h were washed in PBS and solubilized in a buffer containing 
50 mM Tris-HCl (pH 7.4), 150 mM NaCl + 1% TX-100. The catalytic 
core of the deubiquitinating enzyme Usp2 (Usp2-cc; Catanzariti 
et al., 2004; Ryu et al., 2006) was purified and kindly provided by 
Stephen Kaiser (St. Jude Children’s Research Hospital, Memphis, 
TN). Lysate (40 μg) was incubated in the presence or absence of 2 μg 
Usp2-cc for 1 h at 37°C in a buffer containing 50 mM Tris-HCl (pH 7.4), 
150 mM NaCl + 1% TX100 + 5 mM EDTA + 1.4 mM DTT. Deubiquit-
inated proteins were separated by SDS–PAGE and analyzed by 
immunoblotting with anti-CD147 and anti-ubiquitin antibodies.
pRetroQ vector targeting firefly luciferase were generous gifts from 
Albert Koong (Stanford University). The pMSCV vectors targeting 
Hrd1, gp78, XTP3-B, or the control firefly sequence were generated 
by subcloning from pSM2 vectors (gifts from Wade Harper, Harvard 
University), as previously described (Schlabach et al., 2008). Both the 
lentivirus and retrovirus shuttle plasmids were cotransfected into 293T 
cells along with vectors pMD2.VSVG and pCMV-dR.74 or pCG-
GagPol and pVSV-G, respectively, using the calcium-phosphate co-
precipitation technique or Fugene6 (Roche, Indianapolis, IN). Infec-
tious lentivirus or retrovirus particles were concentrated from tissue 
culture supernatants by either ultracentrifugation at 50,000 × g, 16°C, 
in an SW41 rotor (Beckman Coulter, Brea, CA) for 2 h or using 5X PEG-
it (System Biosciences, Mountain View, CA) according to manufactur-
er’s protocol, resuspended in 1X phosphate-buffered saline (PBS) and 
stored at −80°C. Lentiviral titers were determined by infecting HEK293 
cells and measuring green fluorescent protein fluorescence by flow 
cytometry. Retroviral titers were determined by infecting HEK293 cells 
with various dilutions of virus and selecting with 1 μg/ml puromycin.
Cell lysis, SAP, immunoblotting, and MS analysis
cDNA-transfected or virus-transduced HEK293 cells were washed 
once in ice-cold 1X PBS; harvested; and lysed in buffer containing 
50 mM Tris-HCl (pH 7.3), 150 mM NaCl, 5 mM EDTA, protease in-
hibitors (Roche), and either 1% (wt/vol) digitonin (Calbiochem, San 
Diego, CA) or 1% (vol/vol) Triton X-100; and incubated for 1 h at 
4°C. The lysates were cleared by centrifugation at 20,000 × g for 
15 min at 4°C. Protein concentration was measured by bicinchoninic 
acid protein assay (BCA; Pierce, Rockford, IL). Normalized lysates 
were incubated with S-protein agarose (Novagen) for 2–16 h at 4°C 
with mixing, and beads were washed three to five times in lysis buf-
fer containing either 0.1% (wt/vol) digitonin or 1% (vol/vol) Triton 
X-100, depending on the lysis conditions. For immunoblot analysis, 
purified proteins were eluted in Laemmli buffer, separated by SDS–
PAGE, and transferred to polyvinylidene fluoride (PVDF; GE Health-
care Life Sciences, Hercules, CA). The PVDF membranes were 
blocked in 5% nonfat milk and incubated with primary antibodies, 
which were followed by HRP-conjugated secondary antibodies, and 
immunoreactivity was detected using ECL+ chemiluminescence re-
agents (GE Healthcare, Waukesha, WI). For LC-MS/MS analysis, 
1 mg of cell lysate was precleared with 50% (vol/vol) Sephadex 
G-100 beads (Sigma-Aldrich) for 60 min prior to incubation with 
S-protein agarose. The affinity-purified protein complexes were 
washed three times with lysis buffer and then twice in 50 mM 
ammonium bicarbonate (pH 8.0) eluted in 0.1% RapiGest SF 
(Waters, Milford, MA) for 20 h at 37°C, incubated with trypsin for 
16 h at 37°C, and subjected to MS using a linear ion-trap mass 
spectrometer, as previously described (Christianson et al., 2008).
Immunoprecipitation of endogenous CD147
The mouse monoclonal antibodies to CD147 (8G6) or hemaggluti-
nin (HA; 12C5; Sigma-Aldrich), as a control, were purified using the 
Pierce Melon Gel IgG Spin Purification Kit. Antibody (25 μg) was 
then cross-linked to a bead matrix using the Pierce Direct IP kit ac-
cording to the manufacturer’s protocol. After the cells were lysed in 
buffer containing 1% (wt/vol) digitonin, as described above, 250 μg 
soluble lysate was added to the antibody-conjugated matrix, and 
the lysate was incubated for 2 h at 4°C with gentle mixing. The im-
munoprecipitated complexes were washed five times in lysis buffer 
and then eluted with Pierce IgG Elution Buffer. After being neutral-
ized with 1M Tris (pH 9.5) protein, the protein elutes were sepa-
rated by SDS–PAGE in Pierce 5X Loading Buffer, transferred to 
PVDF, and analyzed by immunoblotting. Antibodies from previous 
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